Member Info for sharehead

During discussions with prospective partners, it has also become clear that in OTC markets, the taste masking benefits of the OXPZeroTM technology are of significant interest. There are multiple opportunities in this area including taste masked non-tablet products for cough & cold remedies and taste masked formulations for pain & fever, all areas in which paracetamol based formulations currently dominate because of the ease of masking the taste of paracetamol and where it is not currently viable to incorporate ibuprofen or naproxen. The Company is currently involved in on-going partnership discussions for these applications of its OXPZeroTM technology and will update shareholders in due course.

This is the last holdings list of investor's over 3% and in the absence of a change of major holdings RNS assume is still current, they could now be adding and the free float looks tiny. Woodford Investment Managers 401,597,920 33.31% Mr R Griffiths 173,071,097 14.35% David Norwood 105,938,633 8.79% Marcelo Bravo 65,000,000 5.39% Southern Fox Investments Ltd 51,000,000 4.23% Henderson Global Investors 49,400,000 4.10% Octopus Investments 42,140,345 3.50% Aviva Investors 37,964,329 3.15% Mr R Quested 37,247,753 3.09%

BUY for sure imo. This sp is soooo cheap. SP = cash position for a company Neil Woodford thinks is so good that he holds 33%. I have been in here before and watched it rise from 2p to 12p and i think it will be worth a LOT more than 12p, given no IIs sold at 12p and they will do plenty of due diligence then the drop was probably a result of shorting following the delay. Guessing they are all now closed and BUYing back to ride the good news back up to new highs. Very high expectations here from me for sure ! Atb.

See the 5 million trade from yesterday when sp was still around 2p. Based on the subsequent rise could easily be a BUY. Could be an II taking advantage to load up on the cheap. Think this rise has a long way to go.

HIGHLIGHTS ·    Substantive progress in commercialisation discussions regarding the Company's lead NSAID1 assets, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen ·    Feedback has identified the key precursors to successful partnership outcomes, including: o additional platform development o clarity on regulatory pathway for over the counter (OTC) and Prescription (Rx) product approval ·    Significant progress advancing the OXPzeroTM technology platform: o improvement of drug release in vitro o scale-up and optimisation of the manufacturing process o strengthening of the intellectual property (IP) portfolio ·    Loss before tax to 30 June 2016 of £1.0 million (2015: £2.2 million) reflecting lower R&D activity in the first half compared to the comparative period ·    Well-funded with period-end cash, cash equivalent and deposit balances of £22.1 million (2015: £24.1million) ·    Planning to conduct small-scale exploratory pharmacokinetic (PK) trials to validate the in vivo performance of formulation improvements, with details to be announced separately in due course ·    Ongoing dialogue including the initiation of broader outreach to include the Rx market ·    Proceeding to seek pre-IND meetings with the US FDA to clarify US regulatory pathway

As quickly as it falls. Bad news on delay out the way, well oversold Imo, good news due soon ? Could be an easy multi bag from here I hope in a very solid company with oodles of potential.

This has reversed down trend, as always with aim this is totally oversold. Hoping for 6p before update and then back into a big rise, last high was 12p and only thing that changed was a delay. No holdings rns's means NO IIs sold here, all still holding out for massive potential upside. Gla.

This was 12p and heading up. Maybe some important news leaking here......

* pharmascience

Google Oxford Pharmasvience, under the main link there are options one of which is investor relations I think, its within that.

So thats 79.91% held by investors holding over 3% stake, thats without all us little guys. Free float could be as low as 10% maybe ?

This is the last holdings list of investor's over 3% and in the absence of a change of major holdings RNS assume is still current. Woodford Investment Managers 401,597,920 33.31% Mr R Griffiths 173,071,097 14.35% David Norwood 105,938,633 8.79% Marcelo Bravo 65,000,000 5.39% Southern Fox Investments Ltd 51,000,000 4.23% Henderson Global Investors 49,400,000 4.10% Octopus Investments 42,140,345 3.50% Aviva Investors 37,964,329 3.15% Mr R Quested 37,247,753 3.09%

From July RNS - update could see BIG BOUNCE i hope... The Company is considering, with input from external advisers, its next steps in terms of development and regulatory work and will make further announcements on these processes as appropriate. Oxford Pharmascience remains well-funded to complete this next stage of work, with cash balances as at 30 June 2016 of circa £22.1 million (before receipt of Research and Development tax credit of £0.74 million). During discussions with prospective partners, it has also become clear that in OTC markets, the taste masking benefits of the OXPZeroTM technology are of significant interest. There are multiple opportunities in this area including taste masked non-tablet products for cough & cold remedies and taste masked formulations for pain & fever, all areas in which paracetamol based formulations currently dominate because of the ease of masking the taste of paracetamol and where it is not currently viable to incorporate ibuprofen or naproxen. The Company is currently involved in on-going partnership discussions for these applications of its OXPZeroTM technology and will update shareholders in due course.

Thanks for posting, the 125k rollover was used to disguise all the subsequent BUYs as sells. My theory is that the delay in news was used to hit all stop losses and entice pi's into selling so MMs could collect shares given there is so few in free float. There is no sign that any IIs have reduced holdings here. I feel a really positive update could see a significant bounce, fingers crossed. I have very high hopes as to sp upside here !!

Neil Woodford increased his stake in TRX back in July, who knows he might now INCREASE here.

Yes me too. Entry price is key. I have taken the plunge again on the basis mcap = cash in bank and hopefully that puts a floor around this level, if not i will add in tranches on further dips, however any positive updates could see a good bounce. Until a negative rns released still think this could come very good.

Sometimes the MMs move shares to look like sellers. I don't doubt many pi's have sold, but if a big II had sold we should have had a holdings rns, we could still get one i guess but this has dropped from a high of around 12p to cash in bank value and no holdings rns to date. Other than a delay to seeing this fully commercialised due to pharmas wanting more trials and clarity on regulatory path the potential has not diminished in my view. I have seen drops here reverse and multi bag. A slow drop to 4p once reversed into a rise to 12p. Its a roller coaster ride but still remains a share with massive upside if they can jump through all the hoops and come out the other side. At a mcap that matches cash value, in a very well funded company this is high on my could do really well list !

* long term

He has a huge holding here, in the absence of an RNS stating holding has passed any notifiable threshold I can only assume that he is still invested. He takes a ling term view and my belief is the prospects here remain sound until an RNS suggests otherwise. This could be a huge opportunity and the brave could be well rewarded but we will see.

Very few shares in free float here based on last list I saw of IIs. Do MMs drop this as we have seen in readiness for reversal to collect shares to sell into new rise and given the few shares free the drop is steep as witnessed more than once. Now mcap sat around cash in bank levels. Watch this space.